NeoGenomics (NEO) Stock Forecast & Price Target

Compare

1,910 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

NEO Analyst Ratings

Moderate Buy

5 Buy

6 Hold

0 Sell

Based on 11 analysts giving stock ratings to

NeoGenomics

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

NEO Stock 12 Month Forecast

Average Price Target

$13.67

▲(17.14% Upside)

Based on 11 Wall Street analysts offering 12 month price targets for NeoGenomics in the last 3 months. The average price target is $13.67 with a high forecast of $15.00 and a low forecast of $12.00. The average price target represents a 17.14% change from the last price of $11.67.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"4":"$4","19":"$19","7.75":"$7.75","11.5":"$11.5","15.25":"$15.25"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":15,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$15.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":13.67,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$13.67</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":12,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$12.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[4,7.75,11.5,15.25,19],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Mar<br/>2025","6":"Jun<br/>2025","9":"Sep<br/>2025","12":"Dec<br/>2025","25":"Dec<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,12.02,12.249230769230769,12.478461538461538,12.707692307692307,12.936923076923076,13.166153846153845,13.395384615384614,13.624615384615385,13.853846153846154,14.083076923076923,14.312307692307693,14.541538461538462,14.77076923076923,{"y":15,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,12.02,12.146923076923077,12.273846153846154,12.40076923076923,12.527692307692307,12.654615384615385,12.781538461538462,12.908461538461538,13.035384615384615,13.162307692307692,13.28923076923077,13.416153846153845,13.543076923076923,{"y":13.67,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,12.02,12.018461538461539,12.016923076923076,12.015384615384615,12.013846153846153,12.012307692307692,12.010769230769231,12.009230769230768,12.007692307692308,12.006153846153847,12.004615384615384,12.003076923076923,12.00153846153846,{"y":12,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":18,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 14, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":16.48,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 21, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":14.3,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 21,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 18, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":9.99,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 28,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 14, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":9.35,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 29,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 13, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.26,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 20,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 12, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.17,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 15, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.41,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 18, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.16,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 19, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":8.81,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 15, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":8.72,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 16, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":9.77,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 12, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":12.02,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 12, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target$15.00

Average Price Target$13.67

Lowest Price Target$12.00

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Unknown Analyst

Jefferies

Not Ranked

Jefferies

$15

Buy

28.53%

Upside

Reiterated

12/17/25

Jefferies Keeps Their Buy Rating on NeoGenomics (NEO)

William Bonello

Craig-Hallum

Buy

―

Reiterated

12/15/25

Analysts Offer Insights on Healthcare Companies: Palvella Therapeutics (NASDAQ: PVLA), Champions Oncology (NASDAQ: CSBR) and NeoGenomics (NASDAQ: NEO)

Michael Ryskin

Bank of America Securities

$11→$13

Hold

11.40%

Upside

Reiterated

12/15/25

Bank of America Securities Reaffirms Their Hold Rating on NeoGenomics (NEO)

David Westenberg

Piper Sandler

$11→$12

Buy

2.83%

Upside

Reiterated

11/10/25

NeoGenomics price target raised to $12 from $11 at Piper SandlerNeoGenomics price target raised to $12 from $11 at Piper Sandler

Mark Massaro

BTIG

Hold

―

Reiterated

10/30/25

BTIG Remains a Hold on NeoGenomics (NEO)

Daniel Brennan

TD Cowen

$12→$14

Buy

19.97%

Upside

Reiterated

10/29/25

Strong Growth Prospects for NeoGenomics: Buy Rating with Increased Price Target

Andrew Brackmann

William Blair

Hold

―

Assigned

10/29/25

William Blair Sticks to Their Hold Rating for NeoGenomics (NEO)

Bruce Jackson

Benchmark Co.

Hold

―

Reiterated

10/29/25

Benchmark Co. Reaffirms Their Hold Rating on NeoGenomics (NEO)

Subbu Nambi

Guggenheim

Hold

―

Reiterated

10/28/25

Guggenheim Sticks to Its Hold Rating for NeoGenomics (NEO)

Puneet Souda

Leerink Partners

$12→$14

Hold

19.97%

Upside

Reiterated

10/28/25

Balanced Outlook on NeoGenomics: Hold Rating Amid Growth Potential and Long-Term Skepticism

Michael Matson

Needham

$14

Buy

19.97%

Upside

Reiterated

10/28/25

NeoGenomics' Strong Q3 Performance and Strategic Growth Initiatives Reinforce Buy Rating

Mason Carrico

Stephens

$6.5→$11

Buy

-5.74%

Downside

Reiterated

09/02/25

Stephens Keeps Their Buy Rating on NeoGenomics (NEO)

Yuko Oku

Morgan Stanley

Not Ranked

Morgan Stanley

$10→$8

Hold

-31.45%

Downside

Reiterated

07/30/25

NeoGenomics price target lowered to $8 from $10 at Morgan StanleyNeoGenomics price target lowered to $8 from $10 at Morgan Stanley

Matthew Sykes

Goldman Sachs

$17→$15

Buy

28.53%

Upside

Reiterated

04/16/25

Neogenomics (NEO) PT Lowered to $15 at Goldman SachsGoldman Sachs analyst Matthew Sykes lowered the price target on Neogenomics (NASDAQ: NEO) to $15.00 (from $17.00) while maintaining a Buy rating.

Andrew Cooper

Raymond James

Hold

―

Reiterated

02/18/25

Raymond James reiterates Market Perform Rating on Neogenomics (NEO)Raymond James analyst Andrew Cooper reiterated a Market Perform on Neogenomics (NASDAQ: NEO).

Analyst Type

Any

Human Analysts

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

Unknown Analyst

Jefferies

Not Ranked

Jefferies

$15

Buy

28.53%

Upside

Reiterated

12/17/25

Jefferies Keeps Their Buy Rating on NeoGenomics (NEO)

William Bonello

Craig-Hallum

Buy

―

Reiterated

12/15/25

Analysts Offer Insights on Healthcare Companies: Palvella Therapeutics (NASDAQ: PVLA), Champions Oncology (NASDAQ: CSBR) and NeoGenomics (NASDAQ: NEO)

Michael Ryskin

Bank of America Securities

$11→$13

Hold

11.40%

Upside

Reiterated

12/15/25

Bank of America Securities Reaffirms Their Hold Rating on NeoGenomics (NEO)

David Westenberg

Piper Sandler

$11→$12

Buy

2.83%

Upside

Reiterated

11/10/25

NeoGenomics price target raised to $12 from $11 at Piper SandlerNeoGenomics price target raised to $12 from $11 at Piper Sandler

Mark Massaro

BTIG

Hold

―

Reiterated

10/30/25

BTIG Remains a Hold on NeoGenomics (NEO)

Daniel Brennan

TD Cowen

$12→$14

Buy

19.97%

Upside

Reiterated

10/29/25

Strong Growth Prospects for NeoGenomics: Buy Rating with Increased Price Target

Andrew Brackmann

William Blair

Hold

―

Assigned

10/29/25

William Blair Sticks to Their Hold Rating for NeoGenomics (NEO)

Bruce Jackson

Benchmark Co.

Hold

―

Reiterated

10/29/25

Benchmark Co. Reaffirms Their Hold Rating on NeoGenomics (NEO)

Subbu Nambi

Guggenheim

Hold

―

Reiterated

10/28/25

Guggenheim Sticks to Its Hold Rating for NeoGenomics (NEO)

Puneet Souda

Leerink Partners

$12→$14

Hold

19.97%

Upside

Reiterated

10/28/25

Balanced Outlook on NeoGenomics: Hold Rating Amid Growth Potential and Long-Term Skepticism

Michael Matson

Needham

$14

Buy

19.97%

Upside

Reiterated

10/28/25

NeoGenomics' Strong Q3 Performance and Strategic Growth Initiatives Reinforce Buy Rating

Mason Carrico

Stephens

$6.5→$11

Buy

-5.74%

Downside

Reiterated

09/02/25

Stephens Keeps Their Buy Rating on NeoGenomics (NEO)

Yuko Oku

Morgan Stanley

Not Ranked

Morgan Stanley

$10→$8

Hold

-31.45%

Downside

Reiterated

07/30/25

NeoGenomics price target lowered to $8 from $10 at Morgan StanleyNeoGenomics price target lowered to $8 from $10 at Morgan Stanley

Matthew Sykes

Goldman Sachs

$17→$15

Buy

28.53%

Upside

Reiterated

04/16/25

Neogenomics (NEO) PT Lowered to $15 at Goldman SachsGoldman Sachs analyst Matthew Sykes lowered the price target on Neogenomics (NASDAQ: NEO) to $15.00 (from $17.00) while maintaining a Buy rating.

Andrew Cooper

Raymond James

Hold

―

Reiterated

02/18/25

Raymond James reiterates Market Perform Rating on Neogenomics (NEO)Raymond James analyst Andrew Cooper reiterated a Market Perform on Neogenomics (NASDAQ: NEO).

Stocks with the Highest Top Analyst Consensus in the Sector

Find stocks in the sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering NeoGenomics

1 Month

xxx

Success Rate

9/17 ratings generated profit

Average Return

+4.60%

reiterated a xxx

rating 2 months ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 1 Month would result in 52.94% of your transactions generating a profit, with an average return of +4.60% per trade.

3 Months

xxx

Success Rate

9/19 ratings generated profit

Average Return

+0.56%

reiterated a xxx

rating last month

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 3 Months would result in 47.37% of your transactions generating a profit, with an average return of +0.56% per trade.

1 Year

David WestenbergPiper Sandler

Success Rate

13/19 ratings generated profit

Average Return

+14.85%

reiterated a buy rating last month

Copying David Westenberg's trades and holding each position for 1 Year would result in 68.42% of your transactions generating a profit, with an average return of +14.85% per trade.

2 Years

xxx

Success Rate

10/19 ratings generated profit

Average Return

+1.51%

reiterated a xxx

rating last month

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 2 Years would result in 52.63% of your transactions generating a profit, with an average return of +1.51% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

NEO Analyst Recommendation Trends

Rating

Aug 25

Sep 25

Oct 25

Nov 25

Dec 25

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, NEO has received 9 Buy Ratings, 12 Hold Ratings, and 0 Sell Ratings. NEO average Analyst price target in the past 3 months is 13.67.

Each month's total comprises the sum of three months' worth of ratings.

NEO Financial Forecast

NEO Earnings Forecast

Next quarter’s earnings estimate for NEO is $0.04 with a range of $0.00 to $0.06. The previous quarter’s EPS was $0.03. NEO beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate ― of the time in the same period. In the last calendar year NEO has Performed in-line its overall industry.

NEO Sales Forecast

Next quarter’s sales forecast for NEO is $188.16M with a range of $186.18M to $193.00M. The previous quarter’s sales results were $187.80M. NEO beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates ― of the time in the same period. In the last calendar year NEO has Performed in-line its overall industry.

NEO Stock Forecast FAQ

What is NEO’s average 12-month price target, according to analysts?

Based on analyst ratings, NeoGenomics’s 12-month average price target is 13.67.

What is NEO’s upside potential, based on the analysts’ average price target?

NeoGenomics has 17.14% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is NEO a Buy, Sell or Hold?

NeoGenomics has a consensus rating of Moderate Buy which is based on 5 buy ratings, 6 hold ratings and 0 sell ratings.

What is NeoGenomics’s price target?

The average price target for NeoGenomics is 13.67. This is based on 11 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $15.00 ,the lowest forecast is $12.00. The average price target represents 17.14% Increase from the current price of $11.67.

What do analysts say about NeoGenomics?

NeoGenomics’s analyst rating consensus is a Moderate Buy. This is based on the ratings of 11 Wall Streets Analysts.

How can I buy shares of NEO?

Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.

NeoGenomics (NEO) Stock Forecast & Price Target

NEO Analyst Ratings

NEO Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering NeoGenomics

NEO Analyst Recommendation Trends

NEO Financial Forecast

NEO Earnings Forecast

NEO Sales Forecast

NEO Stock Forecast FAQ

Detailed List of Analyst Forecasts